Angiotensin converting enzyme inhibitors potentiate the vasorelaxant effect of fibrinogen-derived peptide 6A.
Saldeen
K
K
Department of Medicine, University of Florida College of Medicine, Gainesville.
Lawson
D L
DL
Mehta
J L
JL
D000595:Amino Acid Sequence; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D000818:Animals; D001011:Aorta / Q000187:drug effects; D002216:Captopril / Q000008:administration & dosage / Q000031:analogs & derivatives; D004357:Drug Synergism; D015773:Enalaprilat / Q000008:administration & dosage; D005338:Fibrin Fibrinogen Degradation Products / Q000008:administration & dosage* / Q000737:chemistry; D066298:In Vitro Techniques; D008969:Molecular Sequence Data; D051381:Rats; D014664:Vasodilation / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D005338:Fibrin Fibrinogen Degradation Products; C026893:fibrinogen peptide 6A; C044958:zofenopril; D002216:Captopril; D015773:Enalaprilat